drugset / Trial / NCT05557851

Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas

NCT05557851

Phase 1 Unknown 36 enrolled Minneamrita Therapeutics LLC
NaSingle-groupOpen-labelTreatment

Summary

A Phase 1b, Open-Label, Safety, Pharmacokinetic, and Pharmacodynamic Study of an Anti-super-enhancer Minnelide Once a Day on Days 1 to 5, Days 8 to 12 and Days 15 to 19 Along with Abraxane Plus Gemcitabine in Patients with Metastatic Adenocarcinoma of the Pancreas

Timeline

Start
2022-11-01
Primary completion
2024-06
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Minnelide Small molecule
Background Gemcitabine Small molecule
Background Paclitaxel Small molecule